All
How Five-Fraction SBRT Compares With Traditional Radiation in Prostate Cancer
Treatment with five-fraction SBRT for prostate cancer may be more convenient than receiving traditional radiation therapy techniques, an expert said.
Subcutaneous Opdivo Receives FDA Approval for Advanced, Metastatic Solid Tumors
Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.
To Those Facing End of Life From Cancer
We, survivors, often express our gratitude for life, love, support and research, but what about the patients who do not experience positive outcomes from treatment?
FDA Approves Tevimbra Plus Chemo for Gastric, Gastroesophageal Junction Adenocarcinoma
This marks the second FDA approval of Tevimbra this year.
Driven by Experience: How a Caregiver Became an MPN Advocate
An MPN advocate used his personal experiences to inform his dedication to patient-centered research and support programs for patients.
Empowering Patients With MPNs to Participate in Clinical Research
A patient advocate discusses the difficulties of finding and participating in clinical trials for MPNs, and the impact on research and treatment development.
What Patients With Breast Cancer Can Learn From Germline Testing
An expert spoke with CURE® about the importance of information that can be gained from genetic testing for patients with breast cancer.
Reflecting on 2024 Following an Ovarian Cancer Diagnosis
Nearly 12 years after being diagnosed with ovarian cancer, Julie Brokaw believes life is a miracle.
Top 5 Stories from the 2024 San Antonio Breast Cancer Symposium
CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer, in addition to treatment strategies.
How Monjuvi Plus Revlimid, Rituxan Work to Treat Follicular Lymphoma
The treatment combination was found to reduce the risk of follicular lymphoma progression or death by 57%, a study has shown.
Monjuvi Combination May Improve Survival in Follicular Lymphoma
Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.
Top 5 Cancer Vaccine Stories from 2024
With breakthroughs from melanoma to pancreatic cancer, this has been a year of great promise in the field of cancer vaccines.
The Power of Voice in MPN Management
A health care professional talks about the importance of a supportive care team, especially since every patient with MPNs presents differently.
Jace Yawnick of Jace Beats Cancer on the ‘Roller Coaster’ of Life in Remission
After sharing his cancer story online, Jace Yawnick is in a state of technical remission after receiving a diagnosis of non-Hodgkin lymphoma at age 25.
Cancer Memories of a Christmas Past
This Christmas, my wish for all of you is that you read this and feel seen, that someone out there knows how very hard this is for you.
Top 4 Stories From the 2024 ASH Annual Meeting
CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.
Real-World Data May Confirm Monjuvi’s Efficacy in Large B-Cell Lymphoma
The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated, according to data from a retrospective analysis.
FDA Grants Breakthrough Therapy Designation to Trodelvy for Small Cell Lung Cancer
The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who progressed on/after chemotherapy.
Ways to Organize Medical Bills During Cancer
Utilizing tools such as spreadsheet trackers can make a big difference when organizing cancer-related medical bills and noting out-of-pocket maximums.
A Christmas Carol: Lessons Learned From the Past, Present and Future
Watching "Scrooge" every Christmas made me reflect on my own journey, where my past struggles with illness taught me valuable lessons about forgiveness, love and joy.
Top FDA Approvals of Oncology Therapies in 2024
As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.
Epkinly Leads to Responses in Heavily Pretreated Patients With CLL
Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses.
Recognizing Excellence in Oncology Nursing
An oncology nurse demonstrated care not only to her patients with cancer but also to her own staff.
FDA Grants Jemperli Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite instability-high rectal cancer.
Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination.
How to Self Advocate When Insurance Says No to Cancer Treatment Coverage
When insurance denies coverage of cancer treatment, patients with cancer don’t need to take no for an answer, an expert explained.
FDA Approves Braftovi Plus Erbitux and Chemo for Metastatic Colorectal Cancer Subset
Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.
Reflecting on Cancer During a Christmas Morning Run
A reflective Christmas morning run, following a cancer diagnosis, inspires profound gratitude for life and a renewed commitment to living a meaningful life.
NFL Star Randy Moss Undergoing Cancer Treatment, Montell Jordan Shares Update and More
From a Pro Football Hall of Famer announcing his diagnosis to an R&B star’s latest update, here’s what’s happening in the cancer space this week.
Zejula-Jemperli Combo Shows Promising Responses in Breast Cancer Subset
A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, HER2-negative breast cancer.
